MedTrace Logo

Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension

NCT02426099 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2015-04-24

No results posted yet for this study

Summary

This is a four-week randomized controlled single blinded trial of subjects presenting with resistant hypertension in a specialized diabetes care unit of Cameroon. They are randomly assigned using the method of blocks to treatment with a daily 25mg of spironolactone or to routine intensification of antihypertensive regimen , all added to previous regimen with unchanged diet. Visits are scheduled at the start of the treatment, at weeks two and four following add-on therapy initiation. The primary outcome is change in office and self-measurement blood pressure recorded at each visit, and secondary outcomes are variations in serum potassium, sodium, and creatinine levels.

Conditions

Interventions

DRUG

Low dose spironolactone

4-week add-on low dose spironolactone in resistant hypertension

OTHER

Routine intensification of antihypertensive treatment

4-week guidelines oriented intensification of antihypertensive treatment

Sponsors & Collaborators

  • University of Yaounde 1

    collaborator OTHER

  • Sobngwi Eugene

    lead OTHER_GOV

Principal Investigators

  • Jean-Claude Mbanya, MD, PhD · University of Yaounde 1

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Cameroon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426099 on ClinicalTrials.gov